5991-71-9|Clorazepate monopotassium|1H-1,4-Benzodiazepine-3-carboxylic acid, 2,3-dihydro-7-chloro-2-oxo-5-phenyl-, monopotassium salt|-范德生物科技公司

Clorazepate monopotassium

NMR下载 COA and HPLC MSDS下载
names：
1H-1,4-Benzodiazepine-3-carboxylic acid, 2,3-dihydro-7-chloro-2-oxo-5-phenyl-, monopotassium salt
CAS号：
5991-71-9
MDL Number：
MF(分子式)： C16H10ClKN2O3 MW(分子量)： 352.8153
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Clorazepate monopotassium
英文别名	Clorazepate monopotassium; Abbott-39083; Abbott 39083; Abbott39083
CAS号	5991-71-9
Inchi	InChI=1S/C16H11ClN2O3.K/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12;/h1-8,14H,(H,18,20)(H,21,22);/q;+1/p-1
InchiKey	ULEUKTXFAJZAAV-UHFFFAOYSA-M
分子式 Formula	C16H10ClKN2O3
分子量 Molecular Weight	352.8153
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Clorazepate monopotassium(CAS:5991-71-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Clorazepate monopotassium is a minor tranquilizer.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Clorazepate. 2018 Oct 3[1]PMID: 30000269.

[2]Hanna S, Diana F, Slevinski J, Veronich K, Lachman L. Differential pulse polarographic determination of clorazepate monopotassium and dipotassium. J Pharm Sci. 1978 Dec;67(12):1723-5. doi: 10.1002/jps.2600671224. PMID: 31451.

[3] Cohn JB, Bowden CL, Fisher JG, Rodos JJ. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med. 1986 Mar 31;80(3B):10-6. doi: 10.1016/0002-9343(86)90326-8. PMID: 2870640.

[4] Fujii T, Okuno T, Go T, Ochi J, Hattori H, Kataoka K, Mikawa H. Clorazepate therapy for intractable epilepsy. Brain Dev. 1987;9(3):288-91. doi: 10.1016/s0387-7604(87)80046-3. PMID: 2889387.

[5] Elrod L Jr, Shada DM, Taylor VE. High-performance liquid chromatographic analysis of clorazepate dipotassium and monopotassium in solid dosage forms. J Pharm Sci. 1981 Jul;70(7):793-5. doi: 10.1002/jps.2600700721. PMID: 6115049.

6: Forrester SD, Brown SA, Lees GE, Hartsfield SM. Disposition of clorazepate in dogs after single- and multiple-dose oral administration. Am J Vet Res. 1990 Dec;51(12):2001-5. PMID: 2085227.7: Bartenbach DE. Clorazepate dipotassium. Am Fam Physician. 1978 Oct;18(4):43,46,50. PMID: 30272.8: Mimaki T, Tagawa T, Ono J, Tanaka J, Terada H, Itoh N, Yabuuchi H. Antiepileptic effect and serum levels of clorazepate on children with refractory seizures. Brain Dev. 1984;6(6):539-44. doi: 10.1016/s0387-7604(84)80097-2. PMID: 6152517.9: Suzuki EM, Gresham WR. Identification of some interferences in the analysis of clorazepate. J Forensic Sci. 1983 Jul;28(3):655-82. PMID: 6137507.10: Livingston S, Pauli LL. Clorazepate in epilepsy. JAMA. 1977 Apr 11;237(15):1561. PMID: 15140.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开